The post Brandt Issues Warning for Strategy Investors appeared on BitcoinEthereumNews.com. $900 million loss  A trip to $54,000? Veteran trader Peter Brandt hasThe post Brandt Issues Warning for Strategy Investors appeared on BitcoinEthereumNews.com. $900 million loss  A trip to $54,000? Veteran trader Peter Brandt has

Brandt Issues Warning for Strategy Investors

  • $900 million loss 
  • A trip to $54,000?

Veteran trader Peter Brandt has issued a stark warning to Strategy shareholders. 

The chartist recently took to X (formerly Twitter) to question the resolve of investors in Michael Saylor’s company, which has aggressively leveraged its balance sheet to acquire Bitcoin.

“When on this journey will investors want to start jumping from the Sayl_boat? $BTC,” Brandt wrote. “MS will do just great, but what about his investors?”

$900 million loss 

Brandt’s comments come as MicroStrategy’s aggressive accumulation strategy faces its first major stress test of 2026.

According to data from on-chain analytics firm Lookonchain, the recent price plunge has pushed Michael Saylor’s massive Bitcoin treasury into the red. 

You Might Also Like

The 712,647 BTC held by Strategy (formerly MicroStrategy) faced an unrealized loss of over $900 million.

The company itself may be willing to “HODL” through the downturn, but the public market investors who bought MSTR stock as a high-beta proxy for Bitcoin might capitulate if the losses mount.

The shares of the business intelligence firm are now down 72% from the record peak of $543 that was reached back in November 2024. The company has now seen seven consecutive months in the red in a row. 

A trip to $54,000?

The “journey” Brandt refers to is depicted in a terrifying technical chart he shared alongside his warning.

Brandt’s chart shows that the leading cryptocurrency is currently in the process of breaking down from a corrective “bear flag” channel.

BTC has now decisively lost the support of the rising channel that characterized the early 2026 consolidation.

Notably, the chart includes a projected arrow pointing all the way down to $54,059.60.

If this target plays out, it would represent a further 28% drop from current levels. For MicroStrategy, a drop to $54,000 would place their holdings billions of dollars underwater.

Source: https://u.today/brandt-issues-warning-for-strategy-investors

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26